- Visibility 119 Views
- Downloads 125 Downloads
- Permissions
- DOI 10.18231/j.ijmr.12618.1931623825
-
CrossMark
Regenerative medicine in India: A landscape review of scientific progress, regulatory pathways, and future opportunities
- Author Details:
-
Rakesh Pandit *
-
Ashutosh Shukla
-
Nikita Paliya
Rakesh Pandit *
Ashutosh Shukla
Nikita Paliya
India stands at a unique and pivotal crossroads in the global landscape of regenerative medicine. With its vast patient population, skilled scientific workforce, and burgeoning biotechnology sector, the nation holds immense potential to become a leader in this revolutionary field. This comprehensive review synthesizes the current state of regenerative medicine in India, examining the three core pillars that will define its future: scientific progress, regulatory pathways, and persistent challenges. We analyze the significant advancements in stem cell research, particularly with Mesenchymal stem cells (MSCs) across various clinical applications including orthopedics, cardiology, and dermatology and also discuss the emergence of other advanced cell-derived therapies. We then delineate the evolution of India's regulatory framework, from its early, ambiguous phase to the current dual-pronged structure governed by the National guidelines for stem cell research (NGSCR) and the New drugs and clinical trials rules (NDCTR, 2019). This framework critically distinguishes between minimally manipulated cells for autologous use and substantially manipulated cell-based products classified as "drugs." However, significant hurdles remain, including the persistent ethical quandary of "stem cell tourism," a critical deficit in GMP-certified manufacturing facilities, and the "valley of death" in funding that stalls the translation of promising research into clinical therapies. The high cost and affordability of these novel therapies also pose a significant challenge to widespread access. This review concludes that for India to realize its potential, a concerted effort is required from policymakers, scientists, clinicians, and industry stakeholders to strengthen regulatory enforcement, build indigenous manufacturing capacity, foster an ecosystem for innovation streamline commercialization processes, and ultimately ensure that advanced therapies are safe, effective, and accessible to its population.
References
- Mittal S. Stem cell research: the India perspective. Perspect Clin Res. 2013;4(1):105–7.
- Mao AS, Mooney DJ. Regenerative medicine: current therapies and future directions. Proc Natl Acad Sci U S A. 2015;112(47):14452–
- Bauer G, Abou-El-Enein M, Kent A, Poole B, Forte M. The path to successful commercialization of cell and gene therapies: empowering patient advocates. Cytotherapy. 2017;19(2):293–8.
- Tiwari SS, Raman S, Martin P. Regenerative medicine in India: trends and challenges in innovation and regulation. Regen Med. 2017;12(7):875–85.
- Grand View Research. Regenerative Medicine Market Size, Share & Trends Analysis Report. Grand View Research; 2023. Accessed September 19, 2025. https://www.grandviewresearch.com/industry- analysis/regenerative-medicine-market.
- Gupta DR, Singh S. Stem cells: current applications and future prospects. Int J Med Sci. 2023;76(1):2–6.
- Lahiry S, Choudhury S, Sinha R, Chatterjee S. The National Guidelines for Stem Cell Research (2017): what academicians need to know? Perspect Clin Res. 2019;10(4):148–54.
- Coelho A, Alvites RD, Branquinho MV, Guerreiro SG, Maurício AC. Mesenchymal stem cells (MSCs) as a potential therapeutic strategy in COVID-19 patients: literature research. Front Cell Dev Biol. 2020;8:602647.
- Muthu S, Bapat A, Jain R, Jeyaraman N, Jeyaraman M. Exosomal therapy-a new frontier in regenerative medicine. Stem Cell Investig. 2021;8:7.
- Sreenivas A, Jha D. Cell-Free Therapies: Revolutionizing the Approach to Cellular Treatments. In: Advances in Regenerative Medicine and Tissue Engineering. London: IntechOpen; 2025. https://doi.org/10.5772/intechopen.1008700.
- Allan D, Tieu A, Lalu M, Burger D. Mesenchymal stromal cell- derived extracellular vesicles for regenerative therapy and immune modulation: progress and challenges toward clinical application. Stem Cells Transl Med. 2020;9(1):39–46.
- Schmitt A, van Griensven M, Imhoff AB, Buchmann S. Application of stem cells in orthopedics. Stem Cells Int. 2012:394962.
- Malige A, Gates C, Cook JL. Mesenchymal stem cells in orthopaedics: a systematic review of applications to practice. J Orthop. 2024;58:1–9.
- Esquivel D, Mishra R, Srivastava A. Stem cell therapy offers a possible safe and promising alternative approach for treating vitiligo: a review. Curr Pharm Des. 2020;26(37):4815–21.
- Yan W, Xia Y, Zhao H, Xu X, Ma X, Tao L. Stem cell-based therapy in cardiac repair after myocardial infarction: promise, challenges, and future directions. J Mol Cell Cardiol. 2024;188:1–14.
- Arnous S, Mozid A, Martin J, Mathur A. Bone marrow mononuclear cells and acute myocardial infarction. Stem Cell Res Ther. 2012;3(1):2.
- Agosti E, Zeppieri M, Pagnoni A, Fontanella MM, Fiorindi A, Ius T, et al. Current status and future perspectives on stem cell transplantation for spinal cord injury. World J Transplant. 2024;14(1):89674. 322 Pandit et al. / Indian Journal of Microbiology Research 2025;12(3):317–322
- Cherukuri VP, Ch SB, Golla M, Konagala SGS, Penugonda VLDSS, Addanki S. Regulatory Framework for Regenerative Medicine in India. Int J Drug Reg Affairs. 2021;9(3):25-1.
- Khabade AM, Agarwal SS, Mahajan HB, Mandlik SK. Navigating regulatory requirements for stem cells therapy- a review on regulations of US, European Union, Japan and India. Int J Drug Reg Affairs. 2024;12(3):66–81.
- Government of India, Ministry of Health and Family Welfare. New Drugs and Clinical Trials Rules [Internet]. New Delhi: The Ministry; 2019 [cited 2025 Sep 12]. Available from: https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.W EB/elements/download_file_division.jsp?num_id=OTk1Ng==.
- Aly RM. Current state of stem cell-based therapies: an overview. Stem Cell Investig. 2020;7:8.
- Einsiedel EF, Adamson H. Stem cell tourism and future stem cell tourists: policy and ethical implications. Dev World Bioeth. 2012;12(1):35–44.
- Deguchi K, Zambaiti E, De Coppi P. Regenerative medicine: current research and perspective in pediatric surgery. Pediatr Surg Int. 2023;39(1):167.
- Laurencin CT, McClinton A. Regenerative cell-based therapies: cutting edge, bleeding edge, and off the edge. Regen Eng Transl Med. 2020;6(1):78–89.
- Cherukuri VP, Ch SB, Golla M, Konagala SGS, Penugonda VLDSS, Addanki S. Regulatory Framework for Regenerative Medicine in India. Int J Drug Reg Affairs. 2021;9(3):25–31.
- Press Information Bureau, Government of India. CDSCO approves India's first indigenously developed CAR T-cell therapy for commercial use [Internet]. New Delhi: The Bureau; 2023 Oct [cited 2025 Sep 12]. Available from: https://www.pib.gov.in/PressReleasePage.aspx?PRID=2017169.
- Li R, Wang Q, She K, Lu F, Yang Y. CRISPR/Cas systems usher in a new era of disease treatment and diagnosis. Mol Biomed. 2022;3(1):31. Cite this article: Pandit R, Shukla A, Paliya N. Regenerative medicine in India: A landscape review of scientific progress, regulatory pathways, and future opportunities. Indian J Microbiol Res. 2025;12(3):317–322.